E-resources
Peer reviewed
-
Graham, Thomas H.; Shen, Hong C.; Liu, Wensheng; Xiong, Yusheng; Verras, Andreas; Bleasby, Kelly; Bhatt, Urmi R.; Chabin, Renee M.; Chen, Dunlu; Chen, Qing; Garcia-Calvo, Margarita; Geissler, Wayne M.; He, Huaibing; Lassman, Michael E.; Shen, Zhu; Tong, Xinchun; Tung, Elaine C.; Xie, Dan; Xu, Suoyu; Colletti, Steven L.; Tata, James R.; Hale, Jeffrey J.; Pinto, Shirly; Shen, Dong-Ming
Bioorganic & medicinal chemistry letters, 01/2012, Volume: 22, Issue: 1Journal Article
Novel prolylcarboxypeptidase (PrCP) inhibitors with nanomolar IC50 values were prepared by replacing the previously described dichlorobenzimidazole-substituted pyrrolidine amides with a variety of substituted benzylamine amides. In contrast to prior series, the compounds demonstrated minimal inhibition shift in whole serum and minimal recognition by P-glycoprotein (P-gp) efflux transporters. The compounds were also cell permeable and demonstrated in vivo brain exposure. The in vivo effect of compound (S)-6e on weight loss in an established diet-induced obesity (eDIO) mouse model was studied.
